Structures of Cytochrome P450 17A1 With Prostate Cancer Drugs Abiraterone and TOK-001

Nature - United Kingdom
doi 10.1038/nature10743
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors

Scientific Reports
Multidisciplinary
2016English

Synthesis and Biological Evaluations of Putative Metabolically Stable Analogs of VN/124-1 (TOK-001): Head to Head Anti-Tumor Efficacy Evaluation of VN/124-1 (TOK-001) and Abiraterone in LAPC-4 Human Prostate Cancer Xenograft Model

Steroids
Organic ChemistryMolecular BiologyPharmacologyBiochemistryEndocrinologyClinical Biochemistry
2011English

Cytochrome P450 Pharmacogenetics and Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2006English

Crystal Structures of Human Cytochrome P450 2C9 and 3A4 With Bound Ligands

Acta Crystallographica Section A Foundations of Crystallography
2004English

Genetically Engineered Bacterial Cells Co-Expressing Human Cytochrome P450 With NADPH-cytochrome P450 Reductase: Prediction of Metabolism and Toxicity of Drugs in Humans

Drug Metabolism and Pharmacokinetics
PharmacologyPharmaceutical Science
2002English

Cytochrome P450-Mediated Interactions of Monoclonal Antibodies and Small-Molecules Drugs

Clinical pharmacology and therapy
2019English

Structures and Functions of Novel Cytochrome P450 Species Expressed During Flowering

Biotechnology and Biotechnological Equipment
Biotechnology
2000English

Cytochrome P450-17alpha Polymorphism and Risk of Breast Cancer

1999English

SPOP Mutated/ CHD1 Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

Clinical Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy